Kezuka Takeshi, Ishikawa Hitoshi
KEZUKA Eye Clinic, 1-5-7 Mukojima, Sumida-ku, Tokyo, 131-0033, Japan.
Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan.
Jpn J Ophthalmol. 2018 Mar;62(2):101-108. doi: 10.1007/s10384-018-0561-1. Epub 2018 Feb 14.
Anti-myelin-oligodendrocyte glycoprotein (MOG) antibody positive optic neuritis has been established as a new subset of optic neuropathy. Anti-MOG antibodies are usually measured by cell-based assay. Patients with anti-MOG antibody positive optic neuritis respond well to steroid therapy, and, while visual acuity outcomes are favorable, significant visual field defects remain. Furthermore, patients who are anti-MOG antibody positive have higher rates of recurrence compared to antibody negative patients. Based on these findings, anti-MOG antibody positive patients with optic neuritis have the characteristics of good visual outcomes, residual visual field defects, and high risk of recurrence. Tests for anti-MOG antibody are useful for the diagnosis and treatment of optic neuritis.
抗髓鞘少突胶质细胞糖蛋白（MOG）抗体阳性视神经炎已被确认为视神经病变的一个新亚型。抗MOG抗体通常通过基于细胞的检测方法来测定。抗MOG抗体阳性视神经炎患者对类固醇治疗反应良好，虽然视力预后较好，但仍存在明显的视野缺损。此外，抗MOG抗体阳性患者的复发率高于抗体阴性患者。基于这些发现，抗MOG抗体阳性的视神经炎患者具有视力预后良好、残留视野缺损和高复发风险的特点。抗MOG抗体检测对视神经炎的诊断和治疗很有用。
